Justin Vader, MD
Advanced Heart Failure and Transplant Cardiology · Saint Louis, MONPI 1487864138
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.2%), consulting fees and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Abbott at 57.7% of the total. Reporting peaked in 2019 at $2,710 and has fallen 72.3% since, to $752 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in MO, where the typical reported total is $7,967.
Across 67 payments — averaging $113.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- AstraZeneca$1K
- Abiomed$603
- Novartis$271
- Cvrx, Inc.$230
- Ancora Heart, Inc.$229
- plus $667 from 7 others
Across 10 payments — averaging $13,374 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$126K
- Abbott$8K
What the payments were for
- Consulting fees$3,32444%
- Food & beverage$4,27256%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 37 | $4,388 |
| AstraZeneca | 4 | $1,217 |
| Abiomed | 7 | $603 |
| Novartis | 4 | $271 |
| Cvrx, Inc. | 3 | $230 |
| Ancora Heart, Inc. | 2 | $229 |
| Impulse Dynamics (USA) Inc. | 2 | $197 |
| Edwards Lifesciences | 1 | $149 |
| Medtronic(2 entities) | 3 | $143 |
| Actelion Pharmaceuticals US, Inc. | 1 | $143 |
| Boehringer Ingelheim | 1 | $13 |
| Merck | 1 | $12 |
| Endotronix, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartMate 3 Left Ventricular Dev$2,356
- FARXIGA$1,074
- CARDIOMEMS$396
- OPTIMIZER$335
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$289
- ENTRESTO$230
- Impella$229
- AccuCinch$158
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$149
- OPSUMIT$143
- UPTRAVI$143
- Barostim Neo System$129
- CentriMag$128
- HeartMate 3 Left Ventricular Assist Device$125
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$112
How this compares
$7,605 in reported general payments places this provider in the 45th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
See all advanced heart failure and transplant cardiology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 58 | $1,573,081 |
| EntrestoSacubitril/Valsartan | 826 | $846,524 |
| FarxigaDapagliflozin Propanediol | 404 | $343,984 |
| EliquisApixaban | 350 | $312,358 |
| JardianceEmpagliflozin | 274 | $260,150 |
| XareltoRivaroxaban | 76 | $71,426 |
| OzempicSemaglutide | 31 | $35,881 |
| VerquvoVericiguat | 38 | $32,365 |
| CorlanorIvabradine Hcl | 23 | $19,435 |
| Repatha SureclickEvolocumab | 21 | $16,144 |
| Repatha SyringeEvolocumab | 14 | $11,838 |
| DapagliflozinDapagliflozin Propanediol | 20 | $9,949 |
| Everolimus | 12 | $9,658 |
| Praluent PenAlirocumab | 14 | $6,681 |
| Milrinone In 5% DextroseMilrinone Lactate/D5w | 49 | $5,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $271 | $846,524826 claims |
| AstraZenecaFarxiga | $1,217 | $343,984404 claims |
| Boehringer IngelheimJardiance | $13 | $260,150274 claims |
| MerckVerquvo | $12 | $32,36538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.
Other advanced heart failure and transplant cardiology in Saint Louis
- Gregory EwaldSaint Louis$35K
- Sumanth PrabhuSaint Louis$35K
- Nancy SweitzerSaint Louis$32K
- Justin HartupeeSaint Louis$30K
- Kory LavineSaint Louis$12K
- Jonathan MorenoSaint Louis$5K
- Amanda VermaSaint Louis$5K
- Ali JavaheriSaint Louis$4K
- Edward GeltmanSaint Louis$4K
- Joel SchillingSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.